"Ct"

In our intestines, there are a wide variety of intestinal microorganisms, which are called intestinal microflora. Many studies have proved that they play an extremely important role in maintaining normal digestion and absorption, regulating immunity and preventing pathogen invasion.

On April 4, 2015, the 100-year-old active swimmer Mieko Nagaoka (living in Tabushi Town, Yamaguchi Prefecture, Japan) successfully completed the women's 1500-meter freestyle competition and became the world's first swimmer in the age group of 100-104.

Elahere, the first antibody-coupled drug (ADC) for refractory ovarian cancer, has received accelerated approval from the FDA, resulting in substantial tumour shrinkage in 31.7% of patients and complete tumour disappearance in 4.8%.

Pancreatic cancer has long been known as the "king of cancers" due to its poor prognosis. However, a recent study showed that adding Mitazalimab to a modified FOLFIRINOX regimen resulted in control of over 90% of patients with metastatic pancreatic cancer, with 52% of patients experiencing significant tumour shrinkage!

Nectin-4 is an important target that has been shown to be available as a treatment for locally advanced and advanced bladder cancer. Based on this, Padcev (enfortumab-vedotin-ejfv), the first ADC drug (antibody-coupled drug) for uroepithelial carcinoma, has also received accelerated FDA approval for the treatment of locally advanced or advanced bladder cancer in patients who have previously received immune checkpoint inhibitors (PD-L1, PD-1) and platinum-containing chemotherapy before surgery (neoadjuvant therapy) or after surgery (adjuvant therapy). Adult patients with advanced or late-stage uroepithelial carcinoma (a common type of bladder cancer).

The development of an effective anti-aging drug and functional food to slow down ASCs' aging is crucial

Stomach cancer can cause abnormal symptoms in the digestive system, even vomiting blood and black stools, so it should be treated promptly after having stomach cancer

Recently, the US FDA has granted orphan drug status to two new therapeutics in a row. One is a small molecule inhibitor, PCLX-001, for the treatment of acute myeloid leukaemia; the other is a T-cell therapy, ET140203, for the treatment of hepatoblastoma. Both therapies are currently in relevant trials.

Pancreatic cancer is a very complex and common tumour of the pancreas, and the malignancy of this disease is relatively high.

There is an urgent clinical need for new antimicrobial drugs to break through the dilemma of cIAI treatment in children and address the growing challenge of drug resistance.